234 related articles for article (PubMed ID: 12901961)
21. Multilocus loss of heterozygosity allelotypes identify a genetic pathway associated with progression from low to high stage disease in neuroblastoma.
Chughtai SA; Genus T; Ramani P; Dyer S; Powell JE; McMullan D; Davison V; McConville CM;
Eur J Cancer; 2006 Aug; 42(12):1826-34. PubMed ID: 16872824
[TBL] [Abstract][Full Text] [Related]
22. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
23. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
24. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
[TBL] [Abstract][Full Text] [Related]
25. Human neuroblastoma: from basic science to clinical debut of cellular oncogenes.
Schwab M
Naturwissenschaften; 1999 Feb; 86(2):71-8. PubMed ID: 10084150
[TBL] [Abstract][Full Text] [Related]
26. Implication of unfavorable histology, MYCN amplification and diploidy for stage I and II neuroblastomas.
de Buys Roessingh AS; Rougemont AL; Wiesenauer C; Barrette S; Bouron-Dal Soglio D; Lallier M
Eur J Pediatr Surg; 2008 Dec; 18(6):410-4. PubMed ID: 19012235
[TBL] [Abstract][Full Text] [Related]
27. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
28. Evolution of unbalanced gain of distal chromosome 2p in neuroblastoma.
Stallings RL; Carty P; McArdle L; Mullarkey M; McDermott M; O'Meara A; Ryan E; Catchpoole D; Breatnach F
Cytogenet Genome Res; 2004; 106(1):49-54. PubMed ID: 15218241
[TBL] [Abstract][Full Text] [Related]
29. Peripheral neuroblastic tumours in eastern Denmark 1972-2002.
Zimling ZG; Rechnitzer C; Rasmussen M; Petersen BL
APMIS; 2007 Jan; 115(1):66-74. PubMed ID: 17223852
[TBL] [Abstract][Full Text] [Related]
30. The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas.
Weber A; Starke S; Bergmann E; Christiansen H
Clin Cancer Res; 2006 Dec; 12(24):7316-21. PubMed ID: 17189403
[TBL] [Abstract][Full Text] [Related]
31. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
[TBL] [Abstract][Full Text] [Related]
32. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
33. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
[TBL] [Abstract][Full Text] [Related]
34. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma.
Combaret V; Gross N; Lasset C; Frappaz D; Beretta-Brognara C; Philip T; Beck D; Favrot MC
Eur J Cancer; 1997 Oct; 33(12):2101-5. PubMed ID: 9516862
[TBL] [Abstract][Full Text] [Related]
35. Molecular biology of neuroblastoma.
Maris JM; Matthay KK
J Clin Oncol; 1999 Jul; 17(7):2264-79. PubMed ID: 10561284
[TBL] [Abstract][Full Text] [Related]
36. High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.
Tabyaoui I; Tahiri-Jouti N; Serhier Z; El Maani K; Cherkaoui S; Al Zemmouri M; Othmani MB; Zamiati S
Diagn Mol Pathol; 2013 Jun; 22(2):112-8. PubMed ID: 23628823
[TBL] [Abstract][Full Text] [Related]
37. Alternative pathways of MYCN gene copy number increase in primary neuroblastoma tumors.
Valent A; Guillaud-Bataille M; Farra C; Lozach F; Spengler B; Terrier-Lacombe MJ; Valteau-Couanet D; Danglot G; Lenoir GM; Brison O; Bénard J; Bernheim A
Cancer Genet Cytogenet; 2004 Aug; 153(1):10-5. PubMed ID: 15325088
[TBL] [Abstract][Full Text] [Related]
38. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
[TBL] [Abstract][Full Text] [Related]
39. [Amplification of N-myc in neuroblastoma: paradigm for clinical use of an oncogene alteration].
Schwab M
Klin Padiatr; 1990; 202(4):197-201. PubMed ID: 2203936
[TBL] [Abstract][Full Text] [Related]
40. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
